Construct validity showing Spearman correlation coefficients for each measure.
| Source Measure | Pain (VAS or NRS) | Joint Tenderness | Joint Swelling | Activity Limitations* | Patient Global‡ |
|---|---|---|---|---|---|
| MSD | |||||
| Pain (Likert) | NA | 0.34 | 0.18 | NA | NA |
| Joint tenderness | 0.25 | NA | NA | ||
| Joint swelling | NA | NA | |||
| Activity limitations | NA | ||||
| Pfizer | |||||
| Pain (Likert) | NA | 0.36 | 0.18 | NA | NA |
| Joint tenderness | 0.37 | NA | NA | ||
| Joint swelling | NA | NA | |||
| Activity limitations | NA | ||||
| Regeneron | |||||
| Pain (Likert) | 0.75 | NA | NA | 0.31 | NA |
| Pain (NRS) | NA | NA | 0.39 | NA | |
| Joint tenderness | NA | NA | NA | ||
| Joint swelling | NA | NA | |||
| Activity limitations | NA | ||||
| Novartis | |||||
| Pain (VAS) | 0.55 | 0.13 | 0.19 | 0.58 | 0.72 |
| Pain (Likert) | 0.15 | 0.17 | 0.58 | 0.70 | |
| Joint tenderness | 0.46 | 0.18 | 0.56 | ||
| Joint swelling | 0.25 | 0.47 | |||
| Activity limitations | 0.50 | ||||
| AUT | |||||
| Pain VAS | NA | NA | NA | 0.66 | 0.73 |
| Joint tenderness | NA | NA | NA | ||
| Joint swelling | NA | NA | |||
| Activity limitations† | 0.73 |
↵* Activity limitations measured by single 0–10 NRS in Regeneron data, HAQ-II in AUT data, and HAQ-DI in Novartis data.
↵† In addition the HAQ-II correlated highly with measures of specific foot function in this dataset.
↵‡ Changes in each measure were correlated with patient global because the patient global represented perception of change (except for the AUT dataset). NA: measure not available in the dataset; AUT: Auckland University of Technology; VAS: visual analog scale; NRS: numeric rating scale; MSD: Merck Sharp & Dohme Corp.